Karyopharm Therapeutics Inc.
KPTI
$7.46
$1.1518.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 137.27M | 142.13M | 145.24M | 148.44M | 145.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 137.27M | 142.13M | 145.24M | 148.44M | 145.67M |
| Cost of Revenue | -1.41M | 4.59M | 6.01M | 16.72M | 15.75M |
| Gross Profit | 138.68M | 137.54M | 139.23M | 131.72M | 129.92M |
| SG&A Expenses | 110.65M | 113.24M | 115.44M | 118.94M | 122.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 252.48M | 261.07M | 264.68M | 274.41M | 276.62M |
| Operating Income | -115.21M | -118.94M | -119.44M | -125.97M | -130.95M |
| Income Before Tax | -123.57M | -62.50M | -76.37M | -87.18M | -89.63M |
| Income Tax Expenses | -5.00K | 22.00K | 57.00K | 296.00K | 280.00K |
| Earnings from Continuing Operations | -123.57 | -62.52 | -76.42 | -87.48 | -89.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -123.57M | -62.52M | -76.42M | -87.48M | -89.91M |
| EBIT | -115.21M | -118.94M | -119.44M | -125.97M | -130.95M |
| EBITDA | -114.89M | -118.61M | -119.10M | -125.63M | -130.61M |
| EPS Basic | -14.61 | -8.02 | -9.39 | -11.19 | -11.86 |
| Normalized Basic EPS | -9.13 | -8.05 | -9.35 | -10.45 | -10.88 |
| EPS Diluted | -14.69 | -13.34 | -14.70 | -16.47 | -17.10 |
| Normalized Diluted EPS | -9.13 | -7.70 | -9.00 | -10.10 | -10.53 |
| Average Basic Shares Outstanding | 33.82M | 33.27M | 32.49M | 31.75M | 31.05M |
| Average Diluted Shares Outstanding | 33.82M | 35.49M | 34.72M | 33.98M | 33.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |